Goldman Sachs: Raised BeiGene's target price to $408.79, raised profit forecast for 2025-2027.

Goldman Sachs released a research report stating that BeiGene's product sales in the third quarter increased by 40% year-on-year to $1.4 billion, exceeding market expectations. BeiYueze remains the biggest growth driver, with revenue reaching $1 billion for the first time in the quarter, up 51% year-on-year, demonstrating steady growth and market share improvement in the international market, surpassing Imbruvica to become the global leader in the BTK market. Based on strong sales performance, the company has revised its full-year sales guidance from $5-5.3 billion to $5.1-5.3 billion. The bank has adjusted its earnings forecasts for BeiGene in 2025-2027 from $2.69, $6.18, and $7.32 per share to $3.78, $6.26, and $6.64 per share; it maintains a "buy" rating, raising the target price for the US stock from $399.73 to $408.79 and the target price for the A shares from 353.97 yuan to 366.48 yuan.